WHAT THE RECORD AND THE COMMUNITY SAY

The short version

Melanotan II is not an approved medicine anywhere. The University of Arizona ran three small controlled studies with 23 subjects between 1996 and 2000 — that's the controlled human evidence base, in full. What comes after that is animal pharmacology, a body of case reports documenting serious adverse events, and a growing qualitative literature recording what people who self-administer it say happens to them.

This page keeps those two things separate: what research-use communities report (labeled anecdotal), and what the published medical literature has actually documented (cited). Neither section tells anyone to use this peptide, and neither section gives doses. Melanotan II (MT-II) is a non-selective agonist of the melanocortin receptors — MC1R, MC3R, MC4R, and MC5R — and that nonselective binding profile is why it does multiple things at once and why the effects cannot be separated at research doses.

What people report

These are effects reported by the research-use community — anecdotal, not clinical evidence, and not verified by controlled trials. Collected from peptide-user forums and published qualitative analyses of online discussions ^[16][21]. No doses given.

Reported as benefits: rapid, deep tan with little or no sun (very commonly reported as the main reason); much less appetite, sometimes weight loss (very commonly reported, often from the first dose); increased sex drive and, in men, spontaneous erections (commonly reported; women also report heightened arousal); cosmetic satisfaction and confidence cited as the reason many keep using it despite the side effects.

Reported downsides: nausea, sometimes vomiting (very commonly reported, worst in the first days); facial flushing and feeling hot (common, short-lived); existing moles and freckles going darker (very commonly reported, often the first visible sign); new moles appearing — a frequently alarming report, sometimes many at once, often what prompts a doctor visit; selective darkening of lips, gums, scars, and genital skin; uneven or blotchy tan that fades patchily for weeks to months after stopping; fatigue and a flu-like run-down feeling in the first days ('melanotan flu'); injection-site redness and swelling; spontaneous stretching and yawning post-dose (odd but usually described as harmless).

Some users believe a deeper tan protects against burning. That is a user belief, not a demonstrated protection.

Safety and cautions

This section is built from cited studies and published case reports.

New, changing, or darkening moles and melanoma risk. As a nonselective MC1R agonist, Melanotan II drives melanocyte activity throughout the skin. Case reports document eruptive new moles and dysplastic (atypical) moles during use ^[12][13][22], including one report of new moles and darkening of existing ones within 24 hours of a single injection ^[22]. Dermoscopy studies have measured real changes in melanocytic lesions during use. Multiple case reports have documented melanoma and melanoma in situ in users ^[12][22]. The long-term melanoma risk has not been established in a controlled study, but any new or changing mole during or after use warrants prompt dermatological review — especially alongside sun or sunbed exposure. This is the most important caution on this page.

Rhabdomyolysis and acute kidney injury. A published case links a melanotan-II injection to systemic toxicity with rhabdomyolysis — severe muscle breakdown that can damage the kidneys, requiring ICU admission — and a separate case and literature review describe renal infarction associated with the compound ^[9][18]. The mechanisms are not fully established.

Priapism — prolonged, painful erection. Multiple case reports describe priapism after tanning injections ^[10][11][23]. One 2021 case is particularly relevant: a 55-year-old man who had used MT-II for six years developed a 30-hour ischemic priapism requiring surgical decompression at a dose commonly reported in the user community. At 15 weeks follow-up: permanent erectile dysfunction with corpora fibrosis, non-responsive to PDE5 inhibitors ^[11]. Priapism lasting more than four hours is a urological emergency.

Posterior reversible encephalopathy syndrome (PRES). A case report documents PRES — a reversible brain-swelling condition presenting with headache, seizures, visual disturbance, and high blood pressure — in association with melanotan use ^[24]. This fits the compound's reported cardiovascular effects.

Nausea and blood-pressure effects. Animal work on alpha-MSH analogs shows they can raise blood pressure, an effect worsened by impaired nitric-oxide signaling. Combined with the very commonly reported nausea, this points to meaningful cardiovascular and gastrointestinal effects that are poorly characterized in people using unregulated product.

Unregulated product: contamination, mislabeling, unknown content. Analytical studies of melanotan products bought online find inaccurate labeling, variable peptide content, and impurities ^[25]. Because there is no quality control, a buyer cannot know the actual identity, dose, purity, or sterility of what is in the vial — which compounds every other risk.

No approval, unknown long-term safety. Melanotan II has never been approved by the FDA or any other regulator ^[26]. Development did not complete late-phase trials, so long-term safety in humans is simply unknown. It should be treated strictly as an unapproved research chemical.

Then and now

Melanotan II was designed in the late 1980s by Victor Hruby, Mac Hadley, and colleagues at the University of Arizona as a superpotent cyclic analog of the natural pigment-stimulating hormone alpha-MSH, with the original goal of promoting tanning and potentially reducing skin-cancer risk ^[27]. Early human work showed it could darken the skin ^[1], and researchers soon noticed it also triggered erections — which led to small studies in men with erectile dysfunction ^[2][3] and eventually to the development of a derived melanocortin agonist aimed at sexual dysfunction. The original tanning program never reached the market. From the mid-2000s an illicit trade emerged selling the peptide online as unlicensed tanning injections — the so-called 'Barbie drug' — despite repeated warnings from regulators and dermatologists. It remains an unapproved research chemical with no sanctioned medical or cosmetic use.